TY - JOUR
T1 - Vitamin C facilitates direct cardiac reprogramming by inhibiting reactive oxygen species
AU - Fang, Juntao
AU - Yang, Qiangbing
AU - Maas, Renée G C
AU - Buono, Michele
AU - Meijlink, Bram
AU - Lotgerink Bruinenberg, Dyonne
AU - Benavente, Ernest Diez
AU - Mokry, Michal
AU - van Mil, Alain
AU - Qian, Li
AU - Goumans, Marie-José
AU - Schiffelers, Raymond
AU - Lei, Zhiyong
AU - Sluijter, Joost P G
N1 - Publisher Copyright:
© 2024, The Author(s).
PY - 2024/1/17
Y1 - 2024/1/17
N2 - Background: After myocardial infarction, the lost myocardium is replaced by fibrotic tissue, eventually progressively leading to myocardial dysfunction. Direct reprogramming of fibroblasts into cardiomyocytes via the forced overexpression of cardiac transcription factors Gata4, Mef2c, and Tbx5 (GMT) offers a promising strategy for cardiac repair. The limited reprogramming efficiency of this approach, however, remains a significant challenge. Methods: We screened seven factors capable of improving direct cardiac reprogramming of both mice and human fibroblasts by evaluating small molecules known to be involved in cardiomyocyte differentiation or promoting human-induced pluripotent stem cell reprogramming. Results: We found that vitamin C (VitC) significantly increased cardiac reprogramming efficiency when added to GMT-overexpressing fibroblasts from human and mice in 2D and 3D model. We observed a significant increase in reactive oxygen species (ROS) generation in human and mice fibroblasts upon Doxy induction, and ROS generation was subsequently reduced upon VitC treatment, associated with increased reprogramming efficiency. However, upon treatment with dehydroascorbic acid, a structural analog of VitC but lacking antioxidant properties, no difference in reprogramming efficiency was observed, suggesting that the effect of VitC in enhancing cardiac reprogramming is partly dependent of its antioxidant properties. Conclusions: Our findings demonstrate that VitC supplementation significantly enhances the efficiency of cardiac reprogramming, partially by suppressing ROS production in the presence of GMT. Graphical abstract: [Figure not available: see fulltext.].
AB - Background: After myocardial infarction, the lost myocardium is replaced by fibrotic tissue, eventually progressively leading to myocardial dysfunction. Direct reprogramming of fibroblasts into cardiomyocytes via the forced overexpression of cardiac transcription factors Gata4, Mef2c, and Tbx5 (GMT) offers a promising strategy for cardiac repair. The limited reprogramming efficiency of this approach, however, remains a significant challenge. Methods: We screened seven factors capable of improving direct cardiac reprogramming of both mice and human fibroblasts by evaluating small molecules known to be involved in cardiomyocyte differentiation or promoting human-induced pluripotent stem cell reprogramming. Results: We found that vitamin C (VitC) significantly increased cardiac reprogramming efficiency when added to GMT-overexpressing fibroblasts from human and mice in 2D and 3D model. We observed a significant increase in reactive oxygen species (ROS) generation in human and mice fibroblasts upon Doxy induction, and ROS generation was subsequently reduced upon VitC treatment, associated with increased reprogramming efficiency. However, upon treatment with dehydroascorbic acid, a structural analog of VitC but lacking antioxidant properties, no difference in reprogramming efficiency was observed, suggesting that the effect of VitC in enhancing cardiac reprogramming is partly dependent of its antioxidant properties. Conclusions: Our findings demonstrate that VitC supplementation significantly enhances the efficiency of cardiac reprogramming, partially by suppressing ROS production in the presence of GMT. Graphical abstract: [Figure not available: see fulltext.].
KW - Cardiac regeneration
KW - Cardiac reprogramming
KW - ROS
KW - Vitamin C
UR - http://www.scopus.com/inward/record.url?scp=85182426376&partnerID=8YFLogxK
U2 - 10.1186/s13287-023-03615-x
DO - 10.1186/s13287-023-03615-x
M3 - Article
C2 - 38229180
SN - 1757-6512
VL - 15
SP - 19
JO - Stem Cell Research & Therapy [E]
JF - Stem Cell Research & Therapy [E]
IS - 1
M1 - 19
ER -